BioSpace News Archive

Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), announces it has initiated its 10-day, dose-ranging toxicology study, using dogs, for its lead drug candidate MB-204.

Quibim, a global leader in medical imaging analysis, consolidated its growth in the United States by closing 2022 with a 5x revenue growth due to its collaborations with radiologists, hospitals, and top-tier pharmaceutical companies.

Elixirgen Therapeutics, Inc. today announced new data from a Phase 1/2 trial (NCT04211714) showing successful ex vivo telomere elongation with lead asset, EXG-34217 (autologous CD34+ hematopoietic stem cells that have been treated ex vivo with EXG-001), in a patient

Orca Bio, a late-stage biotechnology company developing high-precision cell therapies for the treatment of cancer, genetic blood disorders and autoimmune diseases, today announced that interim clinical data from its Phase 1 multi-center trial of its second investigational cell therapy, Orca-Q, were unveiled in an oral presentation at the 64th American Society of Hematology (ASH) Annual Meeting.

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results of a real-world study showing that patients with chronic lymphocytic leukemia (CLL) treated with first-line acalabrutinib monotherapy were 89 percent more likely to start a next-line treatment than those treated with IMBRUVICA® (ibrutinib).

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today presents the final data from its Phase IIa ALICE trial, investigating iadademstat in combination with azacitidine in elderly or unfit patients with acute myeloid leukemia (AML), at the 64th American Society of Hematology (ASH) Annual Conference.

IDEOlogy Health, a multi-channel medical education company, announced today it will attend the 41st Annual J.P. Morgan Healthcare Conference in San Francisco on January 9th through January 12th, 2023.

Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today presented data on NEO-TRA1, a precision-tuned agonist of the IL-2 receptor beta and gamma subunits that is targeted to and selectively expands inhibitory T-regulatory cells.

New research being presented at the 64th American Society of Hematology Annual Meeting and Exposition draws attention to previously overlooked issues in caring for babies and young people and sheds light on opportunities to improve the outlook for children with health challenges.

METAFORA biosystems announces that its partner Wugen presented data supporting clinical development of WU-NK-101 yesterday for relapsed / refractory AML at the American Society of Hematology’s (ASH) 64th Annual Meeting.